Evidence map›Paper›PMID 31727091›Full record

ArticleJournal of translational medicine2019

Circulating microRNAs as minimal residual disease biomarkers in childhood acute lymphoblastic leukemia.

Andrea Rzepiel, Nóra Kutszegi, András Gézsi, Judit C Sági, Bálint Egyed, György Péter, Henriett Butz, Gábor Nyírő, Judit Müller, Gábor T Kovács and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. MiRNAs in Hematopoiesis and Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2023
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Andrea Rzepiel2nd Department of Paediatrics, Semmelweis University, Budapest, Hungary.
Nóra Kutszegi2nd Department of Paediatrics, Semmelweis University, Budapest, Hungary.
András GézsiMTA-SE Immune-Proteogenomics Extracellular Vesicle Research Group, Budapest, Hungary.
Judit C SágiDepartment of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary.
Bálint Egyed2nd Department of Paediatrics, Semmelweis University, Budapest, Hungary.
György PéterHeim Pál Children's Hospital, Budapest, Hungary.
Henriett ButzDepartment of Laboratory Medicine, Semmelweis University, Budapest, Hungary.
Gábor NyírőMTA-SE Molecular Medicine Research Group, Hungarian Academy of Sciences and Semmelweis University, Budapest, Hungary.
Judit Müller2nd Department of Paediatrics, Semmelweis University, Budapest, Hungary.
Gábor T Kovács2nd Department of Paediatrics, Semmelweis University, Budapest, Hungary.
Csaba SzalaiDepartment of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary.
Ágnes F SemseiDepartment of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary.
Dániel J Erdélyi2nd Department of Paediatrics, Semmelweis University, Budapest, Hungary. erdelyi.daniel@med.semmelweis-univ.hu.ORCID 0000-0001-5544-9209
Semmelweis University · HUBudapest University of Technology and Economics · HUHeim Pál Országos Gyermekgyógyászati Intézet · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTreatment stratification based on bone marrow minimal residual disease (MRD) at set time points has resulted in considerably improved survival in pediatric acute lymphoblastic leukemia (ALL). Treatment response is assessed using bone marrow samples. MicroRNAs (miRs) easily traffic among fluid spaces and are more stable than most other RNA classes. We examined the role of circulating miRs as putative less invasive MRD biomarkers.

methodsIn an exploratory experiment, expression of 46 preselected miRs was studied in platelet-free blood plasma samples of 15 de novo, 5 relapsed ALL patients and 10 controls by Custom TaqMan Array Advanced MicroRNA Card. Based on their high expression in ALL compared to controls, and on the reduction observed along the induction therapy, four miRs were selected for further analyses: miR-128-3p, -181a-5p, -181b-5p and 222-3p. Their expression was measured by qPCR at 4 time points in 27 de novo ALL patients treated in the ALL IC-BFM 2009 study.

resultsThe expression of all 4 miRs significantly decreased over the first week of therapy (miR-128-3p: log

conclusionIn conclusion, these circulating miRs might act as biomarkers of residual leukemia. MiR-128-3p and miR-222-3p in blood predict day 15 flow cytometry MRD results 7 days earlier. Although, their sensitivity falls behind that of bone marrow flow cytometry MRD at day 15.

Indexed as

AdolescentBiomarkers, TumorBlood PlateletsChildChild, PreschoolCirculating MicroRNACohort StudiesFemaleGene Expression Regulation, LeukemicHumansInfantMaleNeoplasm, ResidualPrecursor Cell Lymphoblastic Leukemia-LymphomaPrognosisRisk FactorsBiomarkers, TumorCirculating MicroRNABiomarkerMicroRNAMinimal residual diseasePediatric acute lymphoblastic leukemia

Identifiers

PMID31727091
PMCPMC6854698
OpenAlexW2986273560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.